改进了深度法典相关融合方法,用于检测早期轻度认知障碍
Sreelakshmi Shaji1, Rohini Palanisamy2, Ramakrishnan Swaminathan3
1Non-Invasive Imaging and Diagnostic Laboratory, Department of Applied Mechanics and Biomedical Engineering, Indian Institute of Technology Madras, Chennai, India. lakshminair.here@gmail.com.
Medical & biological engineering & computing
|January 14, 2025
概括
这项研究引入了一种改进的深度正统相关性分析 (CCA) 框架,通过融合大脑成像特征来检测早期轻度认知障碍 (EMCI). 该方法对临床前MCI的自动诊断非常有希望.
科学领域:
- 神经成像是一种神经成像.
- 人工智能在医学中的应用
- 生物医学工程 生物医学工程
背景情况:
- 早期轻度认知障碍 (EMCI) 的检测是具有挑战性的,因为微妙的,广泛的大脑变化.
- 体和侧室是受EMCI影响的关键大脑区域.
- 准确检测EMCI对于及时干预和管理至关重要.
研究的目的:
- 开发和验证一个改进的深度正规相关性分析 (CCA) 框架,以加强EMCI检测.
- 合并磁共振 (MR) 图像特征从体和侧心室,以提高诊断准确度.
- 评估拟议框架的性能与现有的CCA方法进行EMCI识别.
主要方法:
- 从健康对照组和EMCI受试者的结构MR图像进行了预处理.
- 侧心室和体被细分,并提取了特征.
- 基于非线性直角代的深度CCA被用于融合提取的特征.
- 使用极端学习机器分类器来区分健康对照和EMCI受试者.
主要成果:
- 和心室结构的融合特征有效检测到EMCI.
- 改进的深度CCA框架实现了高分类器性能,F分数为82.15%.
- 与EMCI检测中最先进的CCA方法相比,提出的方法显示出更高的性能.
结论:
- 拟议的基于CCA的深度框架显示了临床前MCI的自动诊断的巨大潜力.
- 来自特定大脑区域的特征的融合,如体和侧心室,可以提高EMCI检测的准确性.
- 这种方法为早期准确识别认知障碍提供了一个有希望的工具.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35